05/20/2020/by Jennifer AustinPoseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer
05/20/2020/by Jennifer AustinPoseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer
11/05/2019/by poseida superPoseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting
05/13/2019/by jnellisPoseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma
02/13/2019/by poseida superPoseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks
01/04/2019/by poseida superPoseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions
12/03/2018/by jnellisPoseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
11/29/2018/by jnellisPoseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting
11/05/2018/by jnellisPoseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101
